Head-To-Head Review: Nephros (NASDAQ:NEPH) versus InterCure (NASDAQ:INCR)

InterCure (NASDAQ:INCR) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Volatility and Risk

InterCure has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Insider and Institutional Ownership

8.3% of InterCure shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 6.7% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares InterCure and Nephros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Nephros	4.06%	7.66%	5.86%

Valuation & Earnings

This table compares InterCure and Nephros”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47 million	0.57	-$10.37 million	$0.03	27.07
Nephros	$19.12 million	1.90	$1.19 million	$0.07	47.71

Nephros has lower revenue, but higher earnings than InterCure. InterCure is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for InterCure and Nephros, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1	0	0	0	1.00
Nephros	0	1	1	0	2.50

Nephros has a consensus price target of $6.00, indicating a potential upside of 79.64%. Given Nephros’ stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than InterCure.

Summary

Nephros beats InterCure on 13 of the 14 factors compared between the two stocks.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

About Nephros

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.